Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial
Adnan Nagrial·Oliver Klein·Ashray Gunjur·Michael P. Brown·Sam Harris·Craig Underhill·Robert Zielinski·Damien Kee·Wei‐Sen Lam·Howard Chan·Rosemary Harrup·Jane So·Ian M. Collins·Michael Michael·Fiona Chionh·Charles Uy·John Mariadason·Javier Torres·Mandy L. Ballinger·John P. Grady·Elnaz Tavancheh·Jodie Palmer·David M. Thomas·Kylie Wilkie·Jonathan Cebon·Matteo S. Carlino
Efficacy was limited in what is the largest BTC cohort treated to date with combined anti-CTLA-4/PD-1 blockade. Encouraging activity was observed in the GBC subgroup. Further evaluation of checkpoint inhibition in BTC should focus on GBC patients.